Literature DB >> 20578983

Cancer therapy by targeting hypoxia-inducible factor-1.

Y Li1, D Ye.   

Abstract

Tumors are invariably less well-oxygenated than the normal tissues from which they arose. Hypoxia-inducible factor-1 (HIF-1), a key transcriptional regulator, plays a central role in the adaptation of tumor cells to hypoxia by activating the transcription of genes, which regulate several biological processes including angiogenesis, cell proliferation, survival, glucose metabolism and migration. The expression, activity and stability of HIF-1 is not only induced in response to reduced oxygen availability but also modulated through PI-3K, MAPK, autocrine signaling pathways, E3 ubiquitin ligases, and other regulators. The regulators and effects of HIF-1 in cancer have intensively provided us a new clue for the HIF-1 targeting anticancer therapy. This review evaluates the HIF-1 structure, the regulation mechanisms, the functions in cancer and corresponding anticancer strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578983     DOI: 10.2174/156800910793605857

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  21 in total

1.  Synthesis and evaluation of quinazolin-4-ones as hypoxia-inducible factor-1α inhibitors.

Authors:  Wenwei Huang; Ruili Huang; Matias S Attene-Ramos; Srilatha Sakamuru; Erika E Englund; James Inglese; Christopher P Austin; Menghang Xia
Journal:  Bioorg Med Chem Lett       Date:  2011-07-21       Impact factor: 2.823

Review 2.  Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells.

Authors:  Shanchun Guo; Mingli Liu; Guangdi Wang; Marta Torroella-Kouri; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2012-01-24

3.  Aging is associated with hypoxia and oxidative stress in adipose tissue: implications for adipose function.

Authors:  Le Zhang; Philip J Ebenezer; Kalavathi Dasuri; Sun Ok Fernandez-Kim; Joseph Francis; Nithya Mariappan; Zhanguo Gao; Jianping Ye; Annadora J Bruce-Keller; Jeffrey N Keller
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-17       Impact factor: 4.310

4.  Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature.

Authors:  Lucija Slemc; Tanja Kunej
Journal:  Tumour Biol       Date:  2016-09-19

Review 5.  Role of Notch and its oncogenic signaling crosstalk in breast cancer.

Authors:  Shanchun Guo; Mingli Liu; Ruben R Gonzalez-Perez
Journal:  Biochim Biophys Acta       Date:  2010-12-28

6.  Molecular expression and functional activity of efflux and influx transporters in hypoxia induced retinal pigment epithelial cells.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; V K Chaithanya Ponnaluri; Dhananjay Pal; Mridul Mukherji; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-07-01       Impact factor: 5.875

7.  Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.

Authors:  Ladan Vakil; Reza Najafipour; Nasser Rakhshani; Farhad Zamani; Arman Morakabati; Amir Javadi
Journal:  Tumour Biol       Date:  2016-01-09

Review 8.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

Review 9.  Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells.

Authors:  Weiqiang Zhou; Guangdi Wang; Shanchun Guo
Journal:  Biochim Biophys Acta       Date:  2013-10-30

10.  Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.

Authors:  Yeo-Jung Kim; Hae-June Lee; Tae-Min Kim; T S Karin Eisinger-Mathason; Alexia Y Zhang; Benjamin Schmidt; Daniel L Karl; Michael S Nakazawa; Peter J Park; M Celeste Simon; Sam S Yoon
Journal:  Int J Cancer       Date:  2012-06-26       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.